The Most Important 3-Methyladenine Traps
Likelihood ratio tests were performed to test for differences and interactions. All analyses were performed using STATA/SE (version 10.1 for Windows; StataCorp LP, College Station, USA). A first episode of IPD was identified in 4135 individuals ��18?years of age, corresponding to an average rate of 16/100?000 annually. In the control group, 185 individuals were excluded because of suspected reused personal identification numbers, and another 708 individuals because of death before the date of diagnosis of the corresponding cases. Fifty of the IPD cases and 96 control subjects had records of both COPD and asthma and were excluded from the main Sunitinib cell line analyses. A total of 4085 cases and 40?353 matched controls were subjected to the final analyses. The median age at inclusion was 67?years (range 18�C103?years), and 49.4% were men. Among the cases, 96.4% had bacteraemia, 3.2% had pneumococcal growth in the cerebrospinal fluid (with or without bacteraemia) and 2.4% positive culture from other normally sterile sites (with or without bacteraemia). According to the hospital discharge codes in the Inpatient Registry, 70.7% of the IPD cases had pneumonia, selleck compound 5.9% had meningitis, 2% had miscellaneous foci (e.g. arthritis, peritonitis etc.), and 21.5% had no specific focus (i.e. primary bacteraemia or no recorded focus). Overall 39.5% of the IPD cases had a hospital contact for any of the recorded diseases, >30?days to 5?years before first IPD diagnosis, as compared with 19.5% among control subjects (p?Ceftiofur of whom 57.9% were men, had a history of COPD. Among the cases, 248 (6.1%) had a history of COPD, whereas the corresponding number among the control subjects was 478 (1.2%). This corresponds to a five-fold increase in the risk of acquiring IPD, after adjustment for other co-morbidity, level of education and socio-economic status. The results are outlined in detail in Table?3. The risk of IPD increased with the total number of previous hospital visits for COPD (p?
